Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak ...
• If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a live virtual analyst and investor event to review ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results